Ocuphire Pharma Inc

NASDAQ:OCUP   1:40:28 PM EDT
2.67
-0.03 (-1.11%)
Products

Ocuphire Pharma Inc - Issuance Extends Nyxol's U.S. Patent Protection From 2034 Into 2039 For RM Indication

Published: 08/03/2022 12:51 GMT
Ocuphire Pharma Inc (OCUP) - Ocuphire Extends U.S. Patent Protection for Late-stage Drug Candidate Nyxol® for Reversal of Mydriasis by Five More Years Into 2039 With New Patent Issuance.
Ocuphire Pharma Inc - Issuance Extends Nyxol's U.S. Patent Protection From 2034 Into 2039 for Rm Indication.
Ocuphire Pharma Inc - Growing Patent Estate Eligible for FDA Orange Book Listing.
Ocuphire Pharma Inc - on Track to File NDA for Nyxol in First Indication Rm in Late 2022.
Ocuphire Pharma Inc - Potential Second Half 2023 Approval As Only Eye Dilation Reversal Drop.
Ocuphire Pharma Inc - If Approved, Nyxol Could Be Launched in Second Half of 2023.